Clinical Takeaway
A significant portion of patients diagnosed with cannabis-induced psychosis go on to develop schizophrenia spectrum or bipolar disorder, meaning this initial diagnosis should not be considered a benign or self-limiting condition. Clinicians should treat cannabis-induced psychosis as a potential early warning sign requiring structured follow-up and psychiatric monitoring. Discontinuing cannabis use after such an episode is a critical and evidence-supported clinical priority.
#25 Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.
Citation: Javed Mohammad Saad et al.. Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.. BMC psychiatry. 2026. PMID: 41664079.
Design: 6 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: -2
This meta-analysis provides clinicians with quantified risk data to stratify patients who experience cannabis-induced psychosis, enabling more informed prognostic counseling and identification of those requiring closer psychiatric monitoring for conversion to primary psychotic disorders. The findings establish evidence-based prevalence estimates that can guide treatment intensity and follow-up protocols, addressing the current lack of standardized clinical guidelines for managing cannabis-induced psychosis. Understanding these conversion rates is essential for differentiating transient substance-induced symptoms from prodromal presentations of schizophrenia spectrum and bipolar disorders, which carries substantial implications for long-term treatment planning and patient outcomes.
Quality Gate Alerts:
- Preclinical only
Abstract: BACKGROUND: Distinguishing cannabis-induced psychosis from primary psychiatric disorders is difficult and has significant clinical and prognostic implications. Current treatment approaches lack standardized guidelines, potentially leading to the development of schizophrenia spectrum and bipolar disorder. This study systematically reviews the literature and provides a pooled prevalence of later developing these disorders following a cannabis-induced psychosis diagnosis. METHODS: We systematically reviewed Medline, Embase, Web of Science, Google Scholar, and PsychInfo for studies reporting on a group of patients with cannabis-induced psychosis and subsequent diagnoses of schizophrenia spectrum disorder, bipolar disorder, or both. The search was conducted until January 1, 2025. A modified version of the Newcastle-Ottawa scale was used to assess study quality. Random-effects meta-analyses were conducted to calculate pooled mean prevalence. Random-effects meta-regressions were used to identify predictors of higher prevalence. RESULTS: Our strategy identified 13 studies eligible for inclusion with a total population size of 7,515 which reported a total of 16 outcomes of interest. Among cannabis induced psychosis patients, 20% (95% CI:15.8-29.5%) later received a schizophrenia spectrum diagnosis, 5% (95% CI:2.7-6.9%) bipolar and 63% (95% CI:26.8-90.5%) unspecified (both). Compared to individuals receiving a later schizophrenia spectrum disorder diagnosis, patients were 76% less likely to develop bipolar disorder. Later diagnosis of an unspecified disorder showed an approximate 3 folds higher risk with an ARR of 2.52 (95% CI: 1.03-6.15) compared to schizophrenia spectrum disorder alone. CONCLUSIONS: Approximately one in five patients diagnosed with cannabis-induced psychosis will develop schizophrenia spectrum disorder, while one in twenty will be later diagnosed with bipolar disorder.
🧠 This meta-analysis addresses a clinically important question: among patients presenting with cannabis-induced psychosis, how many subsequently develop schizophrenia spectrum or bipolar disorder? The distinction matters tremendously for prognosis and treatment planning, yet the study highlights a significant methodological challenge—differentiating acute cannabinoid-related psychosis from an underlying primary disorder that may have been unmasked rather than caused by the drug. Key confounders include baseline genetic vulnerability, the difficulty of establishing temporal relationships in retrospective studies, variation in cannabis potency and administration routes, concurrent substance use, and the reality that some patients with emerging schizophrenia or bipolar disorder may have used cannabis as self-medication or prodromal symptom management. For clinicians, this underscores the importance of careful longitudinal follow-up rather than assuming a single episode of cannabis-related psychosis will necessarily resolve completely; a substantial minority of these patients do progress to diagnosed primary psychiatric disorders, making comprehensive psychiatric evaluation, family history assessment, and extended monitoring